MedTrace Logo

ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

NCT04488419 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 554

Last updated 2025-04-04

Study results available
· View outcomes & findings →

Summary

This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.

Conditions

  • Alzheimer Disease
  • Dementia of Alzheimer Type

Interventions

DRUG

ATH-1017

Daily subcutaneous (SC) injection of ATH-1017 in a pre-filled syringe

DRUG

Placebo

Daily subcutaneous (SC) injection of Placebo in a pre-filled syringe

Sponsors & Collaborators

  • Athira Pharma

    lead INDUSTRY

Principal Investigators

  • Javier San Martin, MD · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-28
Primary Completion
2024-07-15
Completion
2024-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04488419 on ClinicalTrials.gov